Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. (13th September 2016)

• Record Type: Journal Article
• Authors: Schirmbeck, Nadine G. D.; Mey, Ulrich J. M.; Olivieri, Attilio; Ko, Yon-Dschun; Kaiser, Ulrich; Flieger, Dimitri; Witzens-Harig, Mathias; Schmidt-Wolf, Ingo G. H.
• Is Part Of: Cancer investigation. Volume 34:Number 8(2016)
• Page Start: 361
• Page End: 372
• Publication Date: 2016-09-13
• Subjects: Lymphomas -- therapy -- treatment -- tumor immunology; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2016.1212062
• Languages: English
• ISSNs: 0735-7907

Abstract

ABSTRACT: This analysis reports on 72 patients with relapsed or refractory non-Hodgkin lymphoma who were treated with R-DHAP salvage chemotherapy regimen followed by high-dose chemotherapy and stem cell transplantation. The overall remission rate was 58.3%. Median time of follow-up was 28.7 months. Median progression-free survival was 29 months, estimated median overall survival was 37 months. Within a matched pair analysis these results were compared to a group that received DHAP salvage therapy without rituximab showing similar overall response rates and better estimated five-year overall survival of 59.2% versus 43.5%. R-DHAP therapy was shown to be effective and feasible with acceptable toxicity.